2013 Fiscal Year Final Research Report
The development of new combination therapy with deferasirox and sorafenib on advanced hepatocellular carcinama
| Project/Area Number |
23590978
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
YAMASAKI Takahiro 山口大学, 医学(系)研究科(研究院), 教授 (00304478)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Naoki 山口大学, 大学教育機構, 講師 (90448283)
TERAI Shuji 山口大学, 大学院医学系研究科, 准教授 (00332809)
SAKAIDA Isao 山口大学, 大学院医学系研究科, 教授 (80263763)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 鉄キレート剤 / CDAAモデル / Deferasirox / Sorafenib / Deferoxamine / DEN肝発癌モデル / 肝細胞癌 |
|---|
| Research Abstract |
Sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC). However, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering an oral iron chelator, deferasirox (DFX), on the effects of sorafenib. The combination of DFX+sorafenib markedly prevented liver fibrosis and preneoplastic lesions better than the other treatments. Furthermore, the combination therapy produced significantly fewer adverse effects such as body weight and hand-foot skin syndrome compared with the sorafenib group. The combination therapy with DFX and sorafenib may be a useful adjuvant therapy to prevent recurrence after curative treatment of HCC.
|
-
[Journal Article] Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma2014
Author(s)
Zaitsu J, Yamasaki T, Saeki I, Harima Y,Iwamoto T, Harima Y, Matsumoto T, Urata Y, Hidaka I, Marumoto Y, Ishikawa T, Takami T, Yamamoto N, Kaino S, Uchida K, Terai S, Sakaida I
-
Journal Title
Hepatol Res
Volume: 44(5)
Pages: 481-90
DOI
Peer Reviewed
-
-
[Journal Article] Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease2013
Author(s)
Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, Marumoto Y, Hidaka I, Urata Y, Ishikawa T, Takami T, Segawa M, Uchida K, Terai S, Kunitugu I, Tanabe T, Sakaida I
-
Journal Title
DOI
Peer Reviewed
-
[Journal Article] Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy : current status in Japan2013
Author(s)
Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T
-
Journal Title
Intern Med
Volume: 52(24)
Pages: 2701-6
Peer Reviewed
-
-
-
[Journal Article] Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study : An analysis of 16 346 treated nodules in 13 283 patients2012
Author(s)
Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A
-
Journal Title
Hepatol Res
Volume: 42(12)
Pages: 1058-64
DOI
Peer Reviewed
-
-
[Journal Article] Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma2012
Author(s)
Yamasaki T, Saeki I, Harima Y, Zaitsu J, Maeda M, Tanimoto H, Iwamoto T, Hidaka I, Urata Y, Ishikawa T, Takami T, Yamaguchi Y, Uchida K, Terai S, Sakaida I
-
Journal Title
J Gastroenterol
Volume: 47(6)
Pages: 715-22
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
